TY  - GEN
AU  - Awad,Mark M
AU  - Chu,Quincy S-C
AU  - Gandhi,Leena
AU  - Stephenson,Joe J
AU  - Govindan,Ramaswamy
AU  - Bradford,Daniel S
AU  - Bonomi,Philip D
AU  - Ellison,David M
AU  - Eaton,Keith D
AU  - Fritsch,Holger
AU  - Munzert,Gerd
AU  - Johnson,Bruce E
AU  - Socinski,Mark A
TI  - An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC)
SN  - 1872-8332
PY  - 2017///1108
KW  - Administration, Intravenous
KW  - Adult
KW  - Aged
KW  - Cell Cycle Proteins
KW  - adverse effects
KW  - Disease-Free Survival
KW  - Female
KW  - Humans
KW  - Lung Neoplasms
KW  - drug therapy
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Recurrence, Local
KW  - Neoplasm Staging
KW  - Protein Serine-Threonine Kinases
KW  - Proto-Oncogene Proteins
KW  - Pteridines
KW  - administration & dosage
KW  - Recurrence
KW  - Small Cell Lung Carcinoma
KW  - Smoking
KW  - epidemiology
KW  - Treatment Failure
KW  - Treatment Outcome
KW  - Polo-Like Kinase 1
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study
UR  - https://doi.org/10.1016/j.lungcan.2016.12.019
ER  -